错配修复与微卫星不稳定性检测用于免疫检查点抑制剂治疗:ASCO对CAP指南的认可
ASCO认可CAP于2022年8月3日发布的关于错配修复(MMR)和微卫星不稳定性(MSI)检测的指南,该指南适用于考虑免疫检查点抑制剂治疗的患者。ASCO认可小组认为CAP指南推荐清晰、全面且基于最相关科学证据。推荐涉及结直肠癌、胃食管癌、小肠癌和子宫内膜癌的检测方法选择,并指出肿瘤突变负荷不作为DNA MMR缺陷的替代指标。
要点
- 结直肠癌推荐MMR免疫组化、MSI聚合酶链反应和MSI二代测序三种检测选项。
- 胃食管癌和小肠癌推荐MMR免疫组化和MSI聚合酶链反应。
- 子宫内膜癌仅推荐MMR免疫组化;其他癌种无方法间推荐。
核心结论
- ASCO认可CAP指南的推荐,认为其清晰、全面且基于最相关科学证据。
研究设计与样本
- ASCO认可小组对CAP指南进行方法学严谨性审查和内容推荐审查。
- CAP指南于2022年8月3日发布,由CAP与分子病理学协会及结直肠癌抗争组织合作制定。
主要发现
- 结直肠癌推荐MMR免疫组化、MSI聚合酶链反应和MSI二代测序作为检测选项。
- 胃食管癌和小肠癌推荐MMR免疫组化和MSI聚合酶链反应。
- 子宫内膜癌仅推荐MMR免疫组化。
- 其他癌种未做出支持任一检测方法优于其他的推荐。
- 不推荐肿瘤突变负荷作为DNA MMR缺陷的替代指标。
关键数值与推荐
- 结直肠癌:MMR免疫组化、MSI聚合酶链反应和MSI二代测序均推荐。
- 胃食管癌和小肠癌:推荐MMR免疫组化和MSI聚合酶链反应。
- 子宫内膜癌:仅推荐MMR免疫组化。
- 其他癌种:未做出支持任一检测方法优于其他的推荐。
- 肿瘤突变负荷:不推荐作为DNA MMR缺陷的替代指标。
临床怎么用
- 若检测到与Lynch综合征一致的MMR缺陷,应告知治疗医生。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The College of American Pathologists (CAP) has developed a guideline on testing for mismatch repair (MMR) and microsatellite instability (MSI) for patients considered for immune checkpoint inhibitor therapy. ASCO has a policy and set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations. METHODS: The CAP guideline was reviewed for developmental rigor by methodologists. An ASCO Endorsement Panel subsequently reviewed the content and the recommendations. RESULTS: The ASCO Endorsement Panel determined that the recommendations from the CAP guideline, published on August 3, 2022, are clear, thorough, and based on the most relevant scientific evidence. ASCO endorses Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: Guideline From the College of American Pathologists in Collaboration With the Association for Molecular Pathology and Fight Colorectal Cancer. RECOMMENDATIONS: Within the guideline, MMR immunohistochemistry (IHC), MSI polymerase chain reaction, and MSI next-generation sequencing are all recommended testing options for colorectal cancer, MMR-IHC and MSI-polymerase chain reaction for gastroesophageal and small bowel cancer, and only MMR-IHC for endometrial cancer. No recommendation in favor of any testing method over another could be made for any other cancer. Tumor mutational burden was not recommended as a surrogate for DNA MMR deficiency. If MMR deficiency consistent with Lynch syndrome is detected, it should be communicated to the treating physician.Additional information is available at www.asco.org/molecular-testing-and-biomarkers-guidelines.
引用
- Vikas P, Messersmith H, Compton C, et al. Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of College of American Pathologists Guideline. J Clin Oncol. 2023. PMID: 36603179. doi:10.1200/JCO.22.02462
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。